세계의 미만성 거대 B세포 림프종 치료제 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 약제 클래스별, 치료법별, 최종사용자별, 지역별, 경쟁별(2020-2030년)
Diffuse Large B-cell Lymphoma Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Therapy, By End-User, By Region and Competition, 2020-2030F
상품코드:1698020
리서치사:TechSci Research
발행일:2025년 03월
페이지 정보:영문 183 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
미만성 거대 B세포 림프종 치료제 세계 시장 규모는 2024년 40억 2,000만 달러로 평가되었습니다. 예측 기간 동안 63억 6,000만 달러에 달하고, 2030년까지7.91%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.
세계 미만성 거대 B세포 림프종(DLBCL) 치료제 시장은 유병률 증가, 표적 치료의 발전, 조기 진단에 대한 인식 증가로 인해 큰 성장을 보이고 있습니다. 비호지킨림프종의 가장 흔한 아형인 DLBCL은 발병률이 급증하면서 효과적인 치료 옵션에 대한 수요가 증가하고 있으며, CAR-T 세포치료제, 이중 특이성 항체, 단일클론항체 등 새로운 치료제의 승인 확대는 생존율 향상과 재발성 또는 불응성 재발성 또는 난치성 환자들에게 새로운 희망을 가져다 주고 있는 것이 이 시장의 성장 동력이 되고 있습니다. 제약회사와 연구기관들은 의약품 개발에 적극적으로 투자하고 있으며, 이는 혁신적인 치료법의 강력한 파이프라인으로 이어지고 있습니다. 개인 맞춤형 의료와 바이오마커 중심의 치료 접근 방식으로의 전환은 시장을 더욱 변화시키고 있으며, 치료 효과를 높이고 부작용을 줄이는 맞춤형 치료를 가능하게 하고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
40억 2,000만 달러
시장 규모 : 2030년
63억 6,000만 달러
CAGR : 2025-2030년
7.91%
급성장 부문
병원?클리닉
최대 시장
북미
시장 성장 촉진요인
미만성 대세포 B세포 림프종(DLBCL) 발생률 증가
주요 시장 이슈
혁신적인 치료법의 높은 비용
주요 시장 동향
면역치료 혁명
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 세계의 미만성 거대 B세포 림프종 치료제 시장 전망
시장 규모와 예측
금액별
시장 점유율과 예측
약제 클래스별(Cisplatin, Carboplatin, 5-fluorouracil, Docetaxel, Paclitaxel, Methotrexate, 기타 약제)
치료법별(표적치료, 면역치료, 화학요법, 기타 치료법)
최종사용자별(병원 및 진료소, 외래 진료 센터, 기타)
지역별
기업별(2024년)
시장 맵
약제 클래스별
치료법별
최종사용자별
지역별
제5장 아시아태평양의 미만성 거대 B세포 림프종 치료제 시장 전망
시장 규모와 예측
금액별
시장 점유율과 예측
약제 클래스별
치료법별
최종사용자별
국가별
아시아태평양 : 국가별 분석
중국
인도
호주
일본
한국
제6장 유럽의 미만성 거대 B세포 림프종 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
프랑스
독일
스페인
이탈리아
영국
제7장 북미의 미만성 거대 B세포 림프종 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
멕시코
캐나다
제8장 남미의 미만성 거대 B세포 림프종 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제9장 중동 및 아프리카의 미만성 거대 B세포 림프종 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트
제10장 시장 역학
성장 촉진요인
과제
제11장 시장 동향과 발전
최근 동향
제품 출시
인수합병(M&A)
제12장 세계의 미만성 거대 B세포 림프종 치료제 시장 : SWOT 분석
제13장 Porter의 Five Forces 분석
업계내 경쟁
신규 참여 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제14장 경쟁 구도
Gilead Sciences Inc
Novartis AG
Pfizer Inc.
Merck & Co. Inc.
GlaxoSmithKline plc
F. Hoffmann-La Roche Ltd.
CTI BioPharma Corp.
Celltrion Healthcare Co. Ltd.
Bristol Myers Squibb Company
AbbVie Inc
제15장 전략적 제안
제16장 리서치사에 대해 & 면책사항
LSH
영문 목차
영문목차
Global Diffuse Large B-cell Lymphoma Therapeutics Market was valued at USD 4.02 Billion in 2024 and is expected to reach USD 6.36 Billion in the forecast period with a CAGR of 7.91% through 2030. The Global Diffuse Large B-cell Lymphoma (DLBCL) Therapeutics Market is experiencing significant growth due to rising incidence rates, advancements in targeted therapies, and increasing awareness about early diagnosis. DLBCL, the most common subtype of non-Hodgkin's lymphoma, has seen a surge in cases, driving demand for effective treatment options. The market is benefiting from the expanding approval of novel therapies, including CAR-T cell treatments, bispecific antibodies, and monoclonal antibodies, which are improving survival rates and offering new hope for patients with relapsed or refractory disease. Pharmaceutical companies and research institutions are actively investing in drug development, leading to a robust pipeline of innovative therapies. The shift toward personalized medicine and biomarker-driven treatment approaches is further revolutionizing the market, enabling tailored therapies that enhance treatment efficacy and reduce adverse effects.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 4.02 Billion
Market Size 2030
USD 6.36 Billion
CAGR 2025-2030
7.91%
Fastest Growing Segment
Hospitals & Clinics
Largest Market
North America
Key Market Drivers
Rising Incidence of Diffuse Large B-cell Lymphoma (DLBCL)
The rising incidence of Diffuse Large B-cell Lymphoma (DLBCL) is a significant driving force behind the growth of the global DLBCL therapeutics market. DLBCL is the most common subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 25% to 30% of all NHL cases worldwide. In the United States, the age-standardized incidence rate for DLBCL is 7.2 per 100,000 individuals, with higher rates observed among non-Hispanic whites (9.2 per 100,000). In the United Kingdom, about 5,000 people are diagnosed with DLBCL annually, representing more than 40% of adult NHL cases. This increasing prevalence is a cause for concern and a catalyst for innovative treatment approaches.
Several factors contribute to the escalating incidence of DLBCL. The aging global population is a significant factor, as DLBCL predominantly affects older adults. Most individuals diagnosed with DLBCL are 65 years or older. As life expectancy increases, the number of older individuals at risk for DLBCL rises, thereby expanding the patient population in need of treatment.
Key Market Challenges
High Cost of Innovative Therapies
The high cost of innovative therapies stands as a significant barrier hindering the global Diffuse Large B-cell Lymphoma (DLBCL) therapeutics market. DLBCL, as one of the most common subtypes of non-Hodgkin lymphoma, necessitates cutting-edge treatments to improve patient outcomes. However, the exorbitant prices associated with these therapies create formidable challenges for both patients and healthcare systems.
In recent years, the development of novel treatments, such as Chimeric Antigen Receptor T-cell therapy (CAR-T therapy) and targeted drugs, has provided new hope for DLBCL patients. CAR-T therapy, for instance, involves genetically modifying a patient's T-cells to attack cancer cells specifically. While these therapies offer remarkable results, they often come with a staggering price tag. CAR-T therapies can cost hundreds of thousands of dollars, putting them out of reach for many patients.
Key Market Trends
Immunotherapy Revolution
The immunotherapy revolution is playing a pivotal role in boosting the global Diffuse Large B-cell Lymphoma (DLBCL) therapeutics market. DLBCL, being a prevalent and aggressive subtype of non-Hodgkin lymphoma, has long posed significant challenges for treatment. However, recent breakthroughs in immunotherapy have transformed the landscape of DLBCL therapeutics.
Immune checkpoint inhibitors, such as nivolumab and pembrolizumab, are among the key drivers of this revolution. These drugs work by blocking specific proteins that inhibit the immune system's response to cancer cells. In DLBCL, they have shown promising results by reinvigorating the body's immune defenses against cancer. Patients who have exhausted conventional treatment options, especially those with relapsed or refractory DLBCL, have witnessed remarkable responses to these immunotherapies.
Another groundbreaking immunotherapy approach in DLBCL is Chimeric Antigen Receptor T-cell therapy (CAR-T therapy). CAR-T therapies, like axicabtagene ciloleucel and tisagenlecleucel, involve genetically modifying a patient's own T-cells to express chimeric antigen receptors that target specific proteins on the surface of DLBCL cells. This precise targeting has led to high response rates and prolonged remissions in some patients, even those with refractory disease.
Key Market Players
Gilead Sciences Inc
Novartis AG
Pfizer Inc.
Merck & Co. Inc.
GlaxoSmithKline plc
F. Hoffmann-La Roche Ltd.
CTI BioPharma Corp.
Celltrion Healthcare Co. Ltd.
Bristol Myers Squibb Company
AbbVie Inc
Report Scope:
In this report, the Global Diffuse Large B-cell Lymphoma Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Global Diffuse Large B-cell Lymphoma Therapeutics Market, By Drug Class:
Cisplatin
Carboplatin
5-fluorouracil
Docetaxel
Paclitaxel
Methotrexate
Other Drugs
Global Diffuse Large B-cell Lymphoma Therapeutics Market, By Therapy:
Targeted Therapy
Immunotherapy
Chemotherapy
Other Therapies
Global Diffuse Large B-cell Lymphoma Therapeutics Market, By End-User:
Hospitals &Clinics
Ambulatory care Centers
Others
Global Diffuse Large B-cell Lymphoma Therapeutics Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Turkey
Egypt
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Diffuse Large B-cell Lymphoma Therapeutics Market.
Available Customizations:
Global Diffuse Large B-cell Lymphoma Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Drug Class (Cisplatin, Carboplatin, 5-fluorouracil, Docetaxel, Paclitaxel, Methotrexate, Other Drugs)
4.2.2. By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Other Therapies)
4.2.3. By End-User (Hospitals & Clinics, Ambulatory care Centers, Others)
4.2.4. By Region
4.2.5. By Company (2024)
4.3. Market Map
4.3.1. By Drug Class
4.3.2. By Therapy
4.3.3. By End-User
4.3.4. By Region
5. Asia Pacific Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class
5.2.2. By Therapy
5.2.3. By End-User
5.2.4. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Drug Class
5.3.1.2.2. By Therapy
5.3.1.2.3. By End-User
5.3.2. India Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Drug Class
5.3.2.2.2. By Therapy
5.3.2.2.3. By End-User
5.3.3. Australia Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Drug Class
5.3.3.2.2. By Therapy
5.3.3.2.3. By End-User
5.3.4. Japan Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Drug Class
5.3.4.2.2. By Therapy
5.3.4.2.3. By End-User
5.3.5. South Korea Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Drug Class
5.3.5.2.2. By Therapy
5.3.5.2.3. By End-User
6. Europe Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Therapy
6.2.3. By End-User
6.2.4. By Country
6.3. Europe: Country Analysis
6.3.1. France Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Therapy
6.3.1.2.3. By End-User
6.3.2. Germany Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Therapy
6.3.2.2.3. By End-User
6.3.3. Spain Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Therapy
6.3.3.2.3. By End-User
6.3.4. Italy Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Drug Class
6.3.4.2.2. By Therapy
6.3.4.2.3. By End-User
6.3.5. United Kingdom Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Drug Class
6.3.5.2.2. By Therapy
6.3.5.2.3. By End-User
7. North America Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Therapy
7.2.3. By End-User
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Therapy
7.3.1.2.3. By End-User
7.3.2. Mexico Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Therapy
7.3.2.2.3. By End-User
7.3.3. Canada Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Therapy
7.3.3.2.3. By End-User
8. South America Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Therapy
8.2.3. By End-User
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Therapy
8.3.1.2.3. By End-User
8.3.2. Argentina Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Therapy
8.3.2.2.3. By End-User
8.3.3. Colombia Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Therapy
8.3.3.2.3. By End-User
9. Middle East and Africa Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Therapy
9.2.3. By End-User
9.2.4. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Therapy
9.3.1.2.3. By End-User
9.3.2. Saudi Arabia Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Therapy
9.3.2.2.3. By End-User
9.3.3. UAE Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Therapy
9.3.3.2.3. By End-User
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global Diffuse Large B-cell Lymphoma Therapeutics Market: SWOT Analysis
